<DOC>
	<DOCNO>NCT00578435</DOCNO>
	<brief_summary>The purpose study determine confirm role bone marrow transplantation treatment disorder red cell hemoglobin include sickle cell anemia , thalassemia diamond blackfan anemia .</brief_summary>
	<brief_title>Allogeneic Bone Marrow Transplantation Treatment Genetic Disorders Erythropoiesis</brief_title>
	<detailed_description>The trial propose single arm phase II treatment protocol design examine engraftment , toxicity graft-versus-host disease follow novel cytoreductive regimen include cyclophosphamide Busulfan treatment patient Severe Sickle Cell Anemia , Thalassemia , Diamond Blackfan Anemia use stem cell transplant derive HLA-genotypically identical sibling . Patients conditioned transplantation cyclophosphamide ( 50 mg/kg/day x 4 day ) , busulfan [ ( &lt; 4 year age 1 mg/kg 4 time per day x 4 day ) , ( &gt; 4 year age 0.8 mg/kg 4 time per day x 4 day ) ] . Patients receive Methotrexate &amp; Cyclosporin-A prophylaxis GvHD GCSF promote engraftment . The preferred source stem cell relate HLA-matched related donor unmodified bone marrow stem cell .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Genetic Diseases , Inborn</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients severe HOMOZYGOUS SICKLE CELL ANEMIA SICKLE/BETA THALASSEMIA Neurologic event ( stroke hemorrhage ) . Abnormal cerebral MRI scan cerebral arteriogram MRI angiographic study ( MRA ) impair neuropsychologic testing . Recurrent acute chest syndrome ( &gt; 2 episode ) Stage III sickle chronic lung disease Sickle cell nephropathy ( moderate severe proteinuria GFR 3050 % predict age . Major visual impairment least one eye bilateral proliferative retinopathy . Osteonecrosis multiple bone Chronic debilitate pain secondary vasoocclusive crisis ( &gt; = 3 episode per year &gt; = 3 year ) Recurrent priapism Alloimmunization development antibody follow chronic transfusion therapy Patients HOMOZYGOUS SICKLE CELL ANEMIA SICKLE/BETA THALASSEMIA follow criterion consider accrual protocol Patients &lt; 2 year high WBC count and/or &gt; 1 episode dactylitis and/or Hgb &lt; 7 g/dl History death sickle cell disease sibship patient Patients BETATHALASSEMIA MAJOR Lucarelli class 1 2 risk status i.e 02 follow factor : hepatomegaly , portal fibrosis , poor chelation therapy Patients DIAMONDBLACKFAN ANEMIA fail conventional therapy . Patients must HLAcompatible related donor . The donor must healthy able undergo general anesthesia . Donors heterozygous sickle cell anemia ( hemoglobin AS ) heterozygous thalassemia acceptable donor . At time referral transplantation , patient must good clinical condition without evidence infection Karnofsky Lansky pediatric performance scale &gt; 70 % Each patient donor must willing participate research subject must sign informed consent form advise nature risk study prior enter protocol . Parents legal guardian patient minor sign consent form advise nature risk study Patients whose life expectancy le 8 week . Patients Karnofsky Lansky performance score &lt; 70 % Patients severe major organ dysfunction : Patients severe renal impairment . This determined creatinine clearance &lt; 70 ml/min/1.73 m2 ( serum creatinine &gt; 1.5 x Normal ) glomerular filtration rate &lt; 30 % predict normal age Inadequate cardiac function determine fractional shortening &lt; 28 % echocardiogram , and/or ejection fraction &lt; 50 % echocardiogram RNCA . Patients FS 2328 % show increase FS response stress supine bicycle ergometer eligible Major liver dysfunction : SGOT &gt; 3 x upper limit normal . Hyperbilirubinemia use exclusion criterion hemolytic component bilirubin . Patients active hepatitis severe liver fibrosis also exclude Severe residual functional neurologic impairment Stage IIIIV sickle chronic lung disease Pregnant lactate woman exclude</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>ERYTHROPOIESIS</keyword>
	<keyword>Genetic Disorders</keyword>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Diamond Blackfan Anemia</keyword>
</DOC>